ENZY up +11.14% percent Today $ENZY High is at 8.16 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 12:19 PM

ENZY up +11.14% percent Today $ENZY High is at 8.16 and the Low 7.32 with current volume of 93,515.

Recent News posted below.

Enzymotec Ltd ENZY other info.
http://investorshangout.com/Enzymotec-Ltd-ENZY-90540/

ENZY Enzymotec Ltd Recent Headline News

Enzymotec's (ENZY) CEO Dr. Ariel Katz on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 13, 12:50PM CST

ENZY: 8.28 (+1.01)

Enzymotec beats by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 6:34AM CST

ENZY: 8.28 (+1.01)

Enzymotec Ltd. Reports Third Quarter 2014 Unaudited Financial Results
GlobeNewswire - Thu Nov 13, 6:30AM CST
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported its financial results for the third quarter ended September 30, 2014.
ENZY: 8.28 (+1.01)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:30PM CST

KSS: 57.63 (+0.51), VTNR: 4.77 (-0.22), TYC: 42.48 (+0.08), SPH: 44.34 (-0.32), FLY: 13.21 (-0.02), ENZY: 8.28 (+1.01), RWLK: 27.46 (-0.44), WMT: 83.43 (+0.47), RSTI: 26.62 (+0.45), SBH: 29.96 (-0.27), HP: 77.85 (-1.16), GIB: 36.66 (+0.45), TDG: 192.23 (-0.22), CLFD: 13.14 (+0.64), HIMX: 6.96 (-0.16), VIAB: 74.48 (+1.52), MMS: 52.53 (-0.04)

Enzymotec Ltd. Initiates Clinical Study of Vayarin(R) in Adult ADHD
GlobeNewswire - Tue Nov 11, 7:38AM CST
Enzymotec Ltd., (Nasdaq:ENZY), a developer, manufacturer, and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced the initiation of a clinical study to evaluate the efficacy of Vayarin(R) in adults with Attention Deficit Hyperactivity Disorder, or ADHD.
ENZY: 8.28 (+1.01)

Enzymotec to Report Third Quarter Fiscal Year 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today announced that the Company will release financial results for the third quarter ended September 30, 2014 on Thursday, November 13, 2014, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer will host a conference call to review the financial results.
ENZY: 8.28 (+1.01)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Class Action Involving Enzymotec Ltd. and a Lead Plaintiff Deadline of November 4, 2014 -- ENZY
GlobeNewswire - Wed Oct 29, 11:17AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"

(NASDAQ:ENZY) that all purchasers of the Company's securities pursuant and/or traceable to the Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period"

, have until November 4, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
ENZY: 8.28 (+1.01)

NOV. 4th DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014
Business Wire - Mon Oct 27, 2:45PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"

(Nasdaq:ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
ENZY: 8.28 (+1.01)

Which Stocks Hurt Billionaire Portfolios the Most in 2014?
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the worst for 19 billionaires who made their money investing.
BID: 40.45 (-0.75), CBI: 53.38 (-0.81), MDR: 4.21 (-0.07), DLIA: 0.10 (-0.01), EOPN: 6.54 (-0.12), PGEM: 12.35 (-0.17), ENZY: 8.28 (+1.01), GNC: 43.02 (-0.32), AMCC: 6.00 (-0.11), HHC: 143.04 (-0.64), LL: 54.01 (-1.20), VLTC: 1.37 (unch), CZR: 15.77 (-0.73), SNSS: 2.49 (+0.82), TWER: 1.45 (unch), SHOS: 14.27 (+0.03), DRYS: 1.41 (unch), CREE: 34.94 (-0.63)

ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Enzymotec Ltd. -- ENZY
GlobeNewswire - Sat Oct 25, 4:49PM CDT
Kahn Swick & Foti, LLC ("KSF"

and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 4, 2014 to file lead plaintiff applications in a securities class action lawsuit against Enzymotec Ltd. (Nasdaq:ENZY), if they purchased the Company's securities in connection with the Company's initial public offering ("IPO"

on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period"

. This action is pending in the United States District Court for the District of New Jersey.
ENZY: 8.28 (+1.01)

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014
Business Wire - Tue Oct 21, 11:52AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"

(NASDAQ:ENZY) pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period"

, have until November 4, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
ENZY: 8.28 (+1.01)

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Enzymotec Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of November 4, 2014 -- ENZY
PR Newswire - Mon Oct 06, 1:33PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Enzymotec Ltd. ("Enzymotec" or the "Company"

(Nasdaq: ENZY) common stock pursuant and/or traceable to the Company's Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about September 27, 2013, and/or investors who purchased shares on the open market between September 27, 2013 and August 4, 2014.
ENZY: 8.28 (+1.01)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Enzymotec Ltd. to Contact Brower Piven Before the November 4, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- ENZY
GlobeNewswire - Sat Oct 04, 7:00AM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Enzymotec Ltd. ("Enzymotec" or the "Company"

(Nasdaq:ENZY) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus ("Offering Documents"

issued in connection with the Company's initial public offering on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period"

.
ENZY: 8.28 (+1.01)

ENZYMOTEC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Enzymotec Ltd.
Business Wire - Fri Oct 03, 5:22PM CDT
Kahn Swick & Foti, LLC ("KSF"

and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 4, 2014 to file lead plaintiff applications in a securities class action lawsuit against Enzymotec Ltd. (Nasdaq: ENZY), if they purchased the Company's securities in connection with the Company's initial public offering ("IPO"

on or about September 27, 2013, and/or on the open market between September 27, 2013 and August 4, 2014, inclusive (the "Class Period"

. This action is pending in the United States District Court for the District of New Jersey.
ENZY: 8.28 (+1.01)

EQUITY ALERT: The Rosen Law Firm Reminds Enzymotec Ltd. Investors of Important Class Action Deadline -- ENZY
GlobeNewswire - Thu Oct 02, 1:13PM CDT
The Rosen Law Firm reminds purchasers of Enzymotec Ltd. securities (Nasdaq:ENZY) during the period from September 27, 2013 through August 4, 2014, of the important November 4, 2014 class action deadline.
ENZY: 8.28 (+1.01)

Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Enzymotec Ltd.
GlobeNewswire - Tue Sep 30, 3:01PM CDT
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Enzymotec Ltd. ("Enzymotec" or the "Company"

and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 or violated the Securities Act of 1933.
ENZY: 8.28 (+1.01)

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Enzymotec Ltd. (ENZY) To Contact The Firm
PR Newswire - Fri Sep 26, 6:30PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Enzymotec Ltd. ("Enzymotec" or the "Company"

(NASDAQ: ENZY) of the November 4, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Enzymotec, certain executives and directors of Enzymotec, and the underwriters of the Company's initial public offering.
ENZY: 8.28 (+1.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...